Citizens analyst Devin Ryan lowered the firm’s price target on Hercules Capital (HTGC) to $22 from $24 and keeps an Outperform rating on the shares. Q1 marks a pivotal quarter for Private Capital, with attention shifting back to strong underlying fundamentals despite recent volatility and concerns around non-traded BDC flows, the analyst tells investors in a research note. With valuation multiples at multi-cycle lows and fundamentals holding up, particularly in institutional fundraising, deployment, and monetization, the gap between perception and reality is expected to narrow, potentially driving a recovery in valuations, the firm says.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTGC:
- Hercules Capital price target lowered to $18 from $19 at Keefe Bruyette
- Hercules Capital Faces Securities Lawsuit Over Alleged Due Diligence and Valuation Misrepresentations
- Hercules Capital price target lowered to $16.50 from $17.50 at Piper Sandler
- Gitlab, Altimmune, Cheniere, Pacific Biosciences, Hercules Shock Wall Street
- HTGC Investor Alert: Hercules Capital Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Valuation Process Deficiencies: Levi & Korsinsky
